Home
HelpEpic Test Code LAB42962 KRAS Mutation Analysis
Additional Codes
RMISCR
Specimen Type
- Pancreatic fluid
- FFPE solid tumor tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
- Fine needle aspirate (FNA): Requisition must note specimen is FNA. Fresh cells in suspension, unstained air-dried smears (approx. 6-8 slides), or FFPE cell blocks are acceptable if pathologist attaches note verifying sample has >30% tumor or abnormal cells (required). Minimum 10^6 cells.
Preferred Container
Sterile Container
Storage Requirements
Refrigerated specimen if not shipping immediately.
Transportation Needs
Refrigerated
Shipping Information
Ship to the following Address
NeoGenomics Laboratories
31 Columbia
Aliso Viejo CA 92656
Clinical Significance
Testing is recommended in colorectal cancer as mutations are associated with resistance and shorter overall survival with EGFR-antagonist therapies such as cetuximab or panitumumab. Testing in non-small cell lung cancer may provide prognostic information and predict poor response to EGFR tyrosine kinase inhibitors.
Test Description
Bi-directional sequencing of exons 2 and 3 of the KRAS gene. High-sensitivity sequencing is used for enhanced detection of mutations in codons 12, 13, 59, and 61. For solid tumors, tumor enrichment is performed before extraction. Testing is available separately or in combination with BRAF, HRAS and NRAS in the RAS/RAF Panel. Testing is approved for specimens from the state of New York.
Methodology
Molecular
CPT Code
81275,81276
Last Updated
15-Feb-17